Masayo Tada, President and CEO PLAY LIST from the beginning Financial Results for Q2 FY2017 (April 1 to September 30, 2017) Financial Results for Q2 FY2017 Financial Results for Q2 FY2017 Sales of Major Products in Japan Sales of Major Products in North America & China Segment Information Ordinary income & Net income attributable to owners of the parent Financial Forecasts for FY2017 Financial Forecasts for FY2017 Segment Information To strengthen robust revenue base Pursue Operational Efficiency in Japan Strengthen Robust Revenue Base in the U.S. Research & Clinical Development Status Reorganization of Research Framework (October 2017) Clinical Development Updates: Psychiatry & Neurology Area Clinical Development Updates: Oncology Area Clinical Development Updates: Other Areas (Diabetes) Clinical Development Updates: Regenerative Medicine/Cell Therapy Other topics Submission Target of Key Late-stage Pipeline (as of October 2017) Appendices Changes from Q2 FY2016 Net Sales by Segment Financial Position / Cash Flows Sales of Major Products in Japan Sales of Major Products in North America & China Segment Information FY2017 / FY2016 Development Pipeline(1) (Psychiatry & Neurology Area)(as of October 30, 2017) Development Pipeline(2) (Oncology Area)(as of October 30, 2017) Development Pipeline(3) (Oncology & Other Areas)(as of October 30, 2017) Napabucasin - Clinical development progress (as of October 30, 2017) Amcasertib, Napabucasin - Clinical development progress (as of October 30, 2017) Napabucasin Phase 1b/2 study (Colorectal Cancer: 246 study) Napabucasin Phase 1b/2 study (Pancreatic Cancer: 118 study) LATUDA(R) (lurasidone) - Clinical development progress (as of October 30, 2017) Product Launch Plan (as of October 2017) Regenerative Medicine/Cell Therapy Business Plan (as of October 2017) Disclaimer Regarding Forward-looking Statements @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Back Next